Articles published by Cassava Sciences, Inc.
Cassava Announces Closure of U.S. Department of Justice Investigation
February 19, 2026
Cassava Announces Agreement to Settle Securities Class Action Litigation
December 23, 2025
Cassava Reports Q3 2025 Financials Results and Provides Business Update
November 12, 2025
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
October 22, 2025
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
March 25, 2025
Cassava Sciences Licenses Simufilam Method of Treatment Patent
February 27, 2025
Cassava Sciences Provides a Business Update
January 07, 2025
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
November 25, 2024
Cassava Sciences to Hold Corporate Update on November 25th
November 24, 2024
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
November 18, 2024
Cassava Sciences Reports Q3 2024 Financial and Operating Results
November 07, 2024
Cassava Sciences Resolves SEC Investigation
September 26, 2024
Cassava Sciences Names Rick Barry as Chief Executive Officer
September 09, 2024